09:46 AM EST - BELLUS Health Inc. : Announced that the first patient has been enrolled in the RELIEF (A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough) Phase 2 study of BLU-5937 in chronic cough. BELLUS Health Inc.
shares T.BLU are trading down $0.06 at $3.00.
